Navigation Links
DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
Date:4/16/2008

RALEIGH, N.C., April 16 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today that Surgi-Vision, Inc., a privately held company of which DARA Biosciences owns approximately 9.8% of the outstanding shares, has entered into a licensing and development agreement with Boston Scientific Corporation (NYSE: BSX) for magnetic resonance imaging (MRI)-safe technology.

Boston Scientific issued a press release yesterday announcing a licensing and development arrangement for magnetic resonance imaging (MRI)-safe technology. Physician implanters have consistently mentioned MRI-safe cardiac devices as a primary unmet clinical need. Under the arrangement, Boston Scientific will gain access to Surgi-Vision's development capabilities and will obtain a license to Surgi-Vision's intellectual property for potential use in its implantable cardiac devices. The two companies will work jointly to develop a commercial application of Surgi-Vision's technology. Previously, Boston Scientific and Surgi-Vision entered into a separate licensing and development agreement, in the area of neuromodulation, in December 2005. A complete copy of Boston Scientific's press release can be found at Boston Scientific's website (http://www.bostonscientific.com ).

DARA has been an investor in Surgi-Vision since 2004. Surgi-Vision is a leader in the development of next generation MRI technologies. In addition to its expertise in MRI-safety for implanted medical devices, Surgi-Vision is at the forefront of a new area of medicine that uses MRI as an imaging platform to perform real-time image-guided therapeutic interventions. This system, currently under development, is known as ClearView. The initial target application for ClearView is in the rapidly growing field of neuromodulation. Using the ClearView system, Surgi-Vision hopes to significantly improve the neurosurgical procedure for placing deep brain stimulation leads (DBS) in the brain. Additional applications under development for ClearView include MRI-guided EP to treat atrial fibrillation and MRI-guided precision delivery of drugs/cell therapies. Surgi-Vision holds extensive intellectual property in advanced MRI technologies, including 14 issued U.S. patents, 18 US patent applications and numerous international filings. Surgi-Vision's work in these fields is augmented by strong research relationships with The Johns Hopkins University, University of California, San Francisco and the University of Utah.

About DARA BioSciencies, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires and develops promising therapeutic molecules. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA has a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com .

About Surgi-Vision, Inc.

Surgi-Vision is a leading developer of next-generation MRI technologies, focused on MRI-safety and MRI-guided therapeutic interventions for neuromodulation, cardiac EP and localized delivery of cell/drug therapies.

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to DARA's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others, DARA's ability to raise capital, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... Cosmetic Town, an online ... According to the senior editor of Cosmetic Tow, “Our forum section is an interactive, ... provide answers to other forum members thinking about having cosmetic surgery. The interaction and ...
(Date:9/18/2017)... ... September 18, 2017 , ... Aegis Therapies, a national leader ... executive team adding a Chief Financial Officer following their announcement on January 1, ... support the strategic growth strategy Aegis has defined for the next several years. ...
(Date:9/18/2017)... ... , ... In the age of digital media, limiting screen time among infants ... and a convenient way to soothe fussy children. , According to a recent study, ... sensory development toys completely. , The study, entitled “Is handheld screen time use associated ...
(Date:9/18/2017)... ... September 18, 2017 , ... While Floridians confront the aftermath ... based company, has launched an aid effort focused on the elderly population that was ... over two days and left thousands homeless and displaced. , “The elderly are often ...
(Date:9/18/2017)... ... September 18, 2017 , ... Dallas and Plano Pet Sitting ... Services . The asset-based purchase combines two of the best reviewed and highly ... Park Cities Pet Sitter, says that it was clear from the outset that acquiring ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: